The Food and Drug Administration (FDA) is reporting that Vibativ (telavancin; Theravance) 250mg per vial strength is being discontinued. The affected product has NDC#62847-002-01. 

Vibativ is indicated for the treatment of adults with complicated skin and skin structure infections due to susceptible gram (+) bacteria. It is also approved to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/HAVP) due to Staphylococcus aureus when alternative treatments are not suitable.

Related Articles

Vibativ in the 750mg per vial strength will continue to be available. 

Telavancin, a lipoglycopeptide antibiotic, inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II. Telvancin also binds to the bacterial membrane and disrupts membrane barrier function.

For more information call (855) 784-7972 or visit